

EPTINEZUMAB

| | |
|-------------------------|--|
| BRAND NAME | VYEPTI |
| DRUG CLASS | Monoclonal antibody (human) for migraine prophylaxis |
| AVAILABILITY | Vial contains 100 mg/1 mL of eptinezumab. Also contains histidine hydrochloride monohydrate, polysorbate-80 and sorbitol. ¹ The solution is clear to slightly opalescent and colourless to brownish-yellow. ¹ |
| WARNING | The occupational hazard of intermittent low dose exposure to eptinezumab is not known. Wear a mask and gloves when preparing the infusion solution to minimise exposure. Anaphylactic reactions may occur. Resuscitation facilities must be readily available. ¹ |
| pH | No information |
| PREPARATION | Dilute before use. ¹ |
| STABILITY | Vial: store at 2 to 8 °C. Do not freeze. Protect from light. ¹ Stable for 2 days below 25 °C and in the outer carton. Do not return to the fridge. ¹ Infusion solution: stable for 8 hours below 25 °C or at 2 to 8 °C. ¹ |
| ADMINISTRATION | |
| IM injection | Not recommended |
| SUBCUT injection | Not recommended |
| IV injection | Not recommended |
| IV infusion | Dilute the dose in 100 mL of sodium chloride 0.9%. Gently invert to mix completely. Do not shake. Infuse over 30 minutes. ¹ Use a low protein-binding 0.2 or 0.22 micrometre inline filter. ¹ |
| COMPATIBILITY | Sodium chloride 0.9% ¹ |
| INCOMPATIBILITY | No information |
| SPECIAL NOTES | Hypersensitivity reactions are common and include angioedema, urticaria, flushing, rash and pruritis. Stop or slow the infusion and treat accordingly. ¹ Severe hypersensitivity and anaphylactic reactions are rare but are a medical emergency. Stop the infusion and commence treatment immediately. ¹ |

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 30/03/2022.